01
Cash & equivalents increased 24.8%
Cash & equivalents changed +24.8% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
$4.1M→$5.1MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTDiaMedica Therapeutics Inc.'s latest supported as-filed period reports net income of -$10.1M, 31.7% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +24.8% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Net income changed -31.7% from the comparable as-filed period.
Operating income changed -31.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
DMAC · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001760123-26-000004SEC ↗10-QAug 10, 2026Period Jun 30, 20260001437749-26-026792SEC ↗8-KAug 10, 2026Period Aug 10, 20260001437749-26-026790SEC ↗4Jun 3, 2026Period Jun 1, 20260001759822-26-000004SEC ↗4Jun 3, 2026Period Jun 1, 20260001341125-26-000002SEC ↗4Jun 3, 2026Period Jun 1, 20260001376847-26-000002SEC ↗4Jun 3, 2026Period Jun 1, 20260001451038-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 10, 2026Filed Aug 12, 2026 | Pauls Dietrich JohnPresident & CEO | Grant Or AwardDirect | 60,200 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +40.0% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed +45.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001872863-26-000004